Keywords
COVID-19
SARS-Cov-2
Skin
Urticaria
How to Cite
Plaudit
Abstract
Objectives: To describe the most frequent dermatological conditions observed in COVID-19 patients and to determine whether their presence could be used to establish an early diagnosis or to predict the progression of the infection.
Methods: There was a review in PubMed/MEDLINE and EMBASE of all the articles that had been published between January 1st and November 1st, 2020, with the search terms focused on “SARS-CoV-2”, “COVID-19” and “Skin diseases”.
Results: Eighty three studies met the inclusion criteria. Skin lesions have been reported in 0.2 % of the patients. The most frequently reported dermatoses were: maculopapular/ morbilliform rashes, urticaria and angioedema, chilblain-like acral pattern, and vesicular lesions. Among researchers, there are differences of opinion about a possible diagnostic or prognostic value of the skin diseases that are associated to the infection.
Conclusions: It is advisable to consider the diagnosis of SARS-CoV-2 infection in patients who call the doctor for skin lesions, urticaria, or angioedema, with or without other symptoms of the infection, especially if there is a previous history of recent exposure to other infected subjects.
References
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin converting enzyme 2 (ECA 2) as a SARS-Cov-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-590. DOI: 10.1007/s00134-020-05985-9
Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 receptor gene ACE 2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45. DOI: 10.1186/s40249-020-00662-x
Allegra A, Asero R, Giovannetti A, Isola S, Gangemi S. Urticaria and coronavirus infection: a lesson from SARS-Cov-2 pandemics. Eur Ann Allergy Clin Immunol. 2021(53):51-54. DOI: 10.23822/EurAnnACI.1764-1489.173
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-1720. DOI: 10.1016/j.jemermed.2020.04.004
Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213. DOI: 10.1111/jdv.16387
Sachdeva M, Gianotti R, Shah M, Bradanini L, Tosi D, Veraldi S, et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. J Dermatol Sci. 2020;98(2):75-81. DOI: 10.1016/j.jdermsci.2020.04.011
Gianotti R. COVID-19 and the skin – heuristic review. DermoSprint. En prensa 2020.
Manalo IF, Smith MK, Cheely J, Jacobs R. Dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020;83(2):700. DOI: 10.1016/j.jaad.2020.04.018
Magro C, Mulvey J, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of 5 cases. Transl Res. 2020;220:1-13. DOI: 10.1016/j.trsl.2020.04.007
Carrascosa JM, Morillas V, Bielsa I, Munera-Campos M. Manifestaciones cutáneas en el contexto de la infección por SARS-CoV-2 (COVID-19). Actas Dermosifilogr. 2020;111(9):734-742. DOI: 10.1016/j.ad.2020.08.002.
Quintana Castanedo L, Feito-Rodriguez M, Valero-López I, Chiloeches-Fernández C, Sendagorta-Cudós E, Herranz-Pinto P. Urticarial exanthema as early diagnostic clue for COVID-19 infection. JAAD Case Rep. 2020;6(6):498-499. DOI: 10.1016/j.jdcr.2020.04.026
Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741. DOI: 10.1111/all.14238
Galvan-Casas C, Catalá A, Carretero-Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa LA, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77. DOI: 10.1111/bjd.19163
Hedou M, Caruzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson-Regnault M. Comment on “Cutaneous Manifestations in COVID-19: a first perspective” by Recalcati S. J Eur Acad Dermatol Venereol. 2020;34(7):e299-e300. DOI: 10.1111/jdv.16519.
Najafzadeh M, Shahzad F, Ghaderi N, Ansari K, Jacob B, Wright A. Urticaria (angioedema) and COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(10):e568-e570. DOI: 101111/jdv.16721.
Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoVID-2 (COVID-19) infection. BMJ Case Rep. 2020;13(7):e236981. DOI: 10.1136/bcr-2020-236981
Dastoli S, Bennardo L, Patruno C, Nistico SP. Are erythema multiforme and urticaria related to a better outcome of COVID-19? Dermatol Ther. 2020;9:e13681. DOI: 10.1111/dth.13681
Wollina U, Serap-Karadag A, Rowland-Payne C,Chiriac A, Lotti T. Cutaneous signs in COVID-19 patients: a review. Dermatol Ther. 2020;33(5):e13549. DOI: 10.1111/dth.13549
van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(7): e300-e301. DOI: 10.1111/jdv.16523
Wedi B, Raap U, Wieczorek D, Kapp A. Urticaria and infections. Allergy Asthma Clin Immunol. 2009;5(1):10. DOI: 10.1186/1710-1492-5-10
Imbalzano E, Casciaro M, Quartuccio S, Minciullo PL, Cascio A, Calapai G, et al. Association between urticaria and virus infections: a systematic review. Allergy Asthma Proc. 2016;37(1):18-22. DOI: 10.2500/aap.2016.37.3915
Zuberbier T, Aberer W, Asero R, Abdul-Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. DOI: 10.1111/all.13397
Abdelmaksoud A, Goldost M, Vestita M. Comment on “COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action”. Dermatol Ther. 2020;33(4): e13360. DOI: 10.1111/dth.13360
Criado PR, Criado AJ, Pincelli TP, Yoshimoto TA, Naufal GGA, Abdala BMZ. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: Rapid and excellent response to omalizumab. Intl J Dermatol. 2020;59(10):1292-1295. DOI:10.1111/ijd.15134.
Criado PR, Pagliari C, Jardim-Criado RF, Franco-Marques G, Belda W. What the physician should know about mast cells, dendritic cells, urticaria and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Dermatol Ther. 2020;33(6): e14068. DOI: 10.1111/dth.14068
Gill MA, Liu AH, Calatroni A, Krouse RZ, Shao B, Schiltz A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141(5):1735-1743. DOI: 10.1016/j.jaci.2017.07.035
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2021 Revista Alergia México